These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 37621757)

  • 21. Serum albumin is the strongest predictor of anti-tumor necrosis factor nonresponse in inflammatory bowel disease in resource-constrained regions lacking therapeutic drug monitoring.
    Kumar P; Vuyyuru SK; Das P; Kante B; Ranjan MK; Thomas DM; Mundhra S; Sahu P; Venigalla PM; Jain S; Goyal S; Golla R; Virmani S; Singh MK; Sachdeva K; Sharma R; Dash NR; Makharia G; Kedia S; Ahuja V
    Intest Res; 2023 Oct; 21(4):460-470. PubMed ID: 36926698
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunomodulator Withdrawal From Anti-TNF Therapy Is Not Associated With Loss of Response in Inflammatory Bowel Disease.
    Mahmoud R; Schultheiss HP; Louwers J; van der Kaaij M; van Hellemondt B; Mahmmod N; van Boeckel P; Jharap B; Fidder H; Oldenburg B
    Clin Gastroenterol Hepatol; 2022 Nov; 20(11):2577-2587.e6. PubMed ID: 35101632
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Current status of novel biologics and small molecule drugs in the individualized treatment of inflammatory bowel disease.
    Xu YH; Zhu WM; Guo Z
    World J Gastroenterol; 2022 Dec; 28(48):6888-6899. PubMed ID: 36632311
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice.
    Gisbert JP; Chaparro M
    J Crohns Colitis; 2020 Jun; 14(5):694-709. PubMed ID: 31777929
    [TBL] [Abstract][Full Text] [Related]  

  • 25. How could nanobiotechnology improve treatment outcomes of anti-TNF-α therapy in inflammatory bowel disease? Current knowledge, future directions.
    Eder P; Zielińska A; Karczewski J; Dobrowolska A; Słomski R; Souto EB
    J Nanobiotechnology; 2021 Oct; 19(1):346. PubMed ID: 34715852
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatments of inflammatory bowel disease toward personalized medicine.
    Kim KU; Kim J; Kim WH; Min H; Choi CH
    Arch Pharm Res; 2021 Mar; 44(3):293-309. PubMed ID: 33763844
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative Safety of Biologic Agents in Patients With Inflammatory Bowel Disease With Active or Recent Malignancy: A Multi-Center Cohort Study.
    Holmer AK; Luo J; Russ KB; Park S; Yang JY; Ertem F; Dueker J; Nguyen V; Hong S; Zenger C; Axelrad JE; Sofia A; Petrov JC; Al-Bawardy B; Fudman DI; Llano E; Dailey J; Jangi S; Khakoo N; Damas OM; Barnes EL; Scott FI; Ungaro RC; Singh S;
    Clin Gastroenterol Hepatol; 2023 Jun; 21(6):1598-1606.e5. PubMed ID: 36642291
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Response to Biologic Drugs in Patients With Rheumatoid Arthritis and Antidrug Antibodies.
    Bitoun S; Hässler S; Ternant D; Szely N; Gleizes A; Richez C; Soubrier M; Avouac J; Brocq O; Sellam J; de Vries N; Huizinga TWJ; Jury EC; Manson JJ; Mauri C; Matucci A; Hacein Bey Abina S; Mulleman D; Pallardy M; Broët P; Mariette X;
    JAMA Netw Open; 2023 Jul; 6(7):e2323098. PubMed ID: 37436748
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Study of tumor necrosis factor receptor in the inflammatory bowel disease.
    Souza RF; Caetano MAF; Magalhães HIR; Castelucci P
    World J Gastroenterol; 2023 May; 29(18):2733-2746. PubMed ID: 37274062
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Implications for sequencing of biologic therapy and choice of second anti-TNF in patients with inflammatory bowel disease: results from the IMmunogenicity to Second Anti-TNF therapy (IMSAT) therapeutic drug monitoring study.
    Chanchlani N; Lin S; Auth MK; Lee CL; Robbins H; Looi S; Murugesan SV; Riley T; Preston C; Stephenson S; Cardozo W; Sonwalkar SA; Allah-Ditta M; Mansfield L; Durai D; Baker M; London I; London E; Gupta S; Di Mambro A; Murphy A; Gaynor E; Jones KDJ; Claridge A; Sebastian S; Ramachandran S; Selinger CP; Borg-Bartolo SP; Knight P; Sprakes MB; Burton J; Kane P; Lupton S; Fletcher A; Gaya DR; Colbert R; Seenan JP; MacDonald J; Lynch L; McLachlan I; Shields S; Hansen R; Gervais L; Jere M; Akhtar M; Black K; Henderson P; Russell RK; Lees CW; Derikx LAAP; Lockett M; Betteridge F; De Silva A; Hussenbux A; Beckly J; Bendall O; Hart JW; Thomas A; Hamilton B; Gordon C; Chee D; McDonald TJ; Nice R; Parkinson M; Gardner-Thorpe H; Butterworth JR; Javed A; Al-Shakhshir S; Yadagiri R; Maher S; Pollok RCG; Ng T; Appiahene P; Donovan F; Lok J; Chandy R; Jagdish R; Baig D; Mahmood Z; Marsh L; Moss A; Abdulgader A; Kitchin A; Walker GJ; George B; Lim YH; Gulliver J; Bloom S; Theaker H; Carlson S; Cummings JRF; Livingstone R; Beale A; Carter JO; Bell A; Coulter A; Snook J; Stone H; Kennedy NA; Goodhand JR; Ahmad T;
    Aliment Pharmacol Ther; 2022 Oct; 56(8):1250-1263. PubMed ID: 36039036
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Management of inflammatory bowel disease beyond tumor necrosis factor inhibitors: novel biologics and small-molecule drugs.
    Na SY; Kim YS
    Korean J Intern Med; 2022 Sep; 37(5):906-919. PubMed ID: 35945034
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Optimization of biologics to reduce treatment failure in inflammatory bowel diseases.
    Bourchany A; Gilletta De Saint-Joseph C; Breton A; Barreau F; Mas E
    Curr Opin Pharmacol; 2020 Oct; 54():51-58. PubMed ID: 32947075
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative Risk of Serious Infections With Biologic and/or Immunosuppressive Therapy in Patients With Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis.
    Singh S; Facciorusso A; Dulai PS; Jairath V; Sandborn WJ
    Clin Gastroenterol Hepatol; 2020 Jan; 18(1):69-81.e3. PubMed ID: 30876964
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predictors of Treatment Change Among Patients with Rheumatoid Arthritis Treated with TNF Inhibitors as First-Line Biologic Agent in the USA: A Cohort Study from Longitudinal Electronic Health Records.
    Jin Y; Landon JE; Krueger W; Liede A; Desai RJ; Kim SC
    BioDrugs; 2022 Jul; 36(4):521-535. PubMed ID: 35771381
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of Combination Therapy With Immunomodulators on Trough Levels and Antibodies Against Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Disease: A Meta-analysis.
    Qiu Y; Mao R; Chen BL; Zhang SH; Guo J; He Y; Zeng ZR; Ben-Horin S; Chen MH
    Clin Gastroenterol Hepatol; 2017 Sep; 15(9):1359-1372.e6. PubMed ID: 28232073
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Incidence of suboptimal response to tumor necrosis factor antagonist therapy in inflammatory bowel disease in newly industrialised countries: The EXPLORE study.
    Yamamoto-Furusho JK; Al Harbi O; Armuzzi A; Chan W; Ponce de Leon E; Qian J; Shapina M; Toruner M; Tu CH; Ye BD; Guennec M; Sison C; Demuth D; Fadeeva O; Khan QMR
    Dig Liver Dis; 2020 Aug; 52(8):869-877. PubMed ID: 32563721
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dual-Targeted Therapy in Pediatric Inflammatory Bowel Disease: A Comprehensive Review.
    Yerushalmy-Feler A; Brauner C; Cohen S
    Paediatr Drugs; 2023 Sep; 25(5):489-498. PubMed ID: 37318737
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Proactive Therapeutic Drug Monitoring Versus Conventional Management for Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis.
    Nguyen NH; Solitano V; Vuyyuru SK; MacDonald JK; Syversen SW; Jørgensen KK; Crowley E; Ma C; Jairath V; Singh S
    Gastroenterology; 2022 Oct; 163(4):937-949.e2. PubMed ID: 35753383
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tumour necrosis factor (TNF) antagonist therapy for paediatric inflammatory bowel disease: A systematic review.
    Martín-García P; Alonso-Arroyo A; Catalá-López F
    Med Clin (Barc); 2023 Jun; 160(11):501-516. PubMed ID: 36967304
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Does the Antitumor Necrosis Factor-α Therapy Decrease the Vertebral Fractures Occurrence in Inflammatory Bowel Disease?
    Maldonado-Pérez MB; Castro-Laria L; Caunedo-Álvarez A; Montoya-García MJ; Giner-García M; Argüelles-Arias F; Romero-Gómez M; Vázquez-Gámez MÁ
    J Clin Densitom; 2019; 22(2):195-202. PubMed ID: 30205986
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.